The prostate cancer therapeutics market will reach $7.7bn in 2015

Monday 4 November 2013, Amsterdam

This new report predicts that the world prostate cancer therapeutics market will reach $7.7bn in 2015. Those forecasts and others appear in The Prostate Cancer Therapeutics Market 2013-2023, published in September 2013. The prostate cancer therapeutics market will have significant opportunities for growth. This report believes that market expansion will be driven by drugs targeting the castration-resistant prostate cancer market. Prostate cancer generally affects people above 65 and statistics suggest that between 2000 and 2050, the number of men aged above 65 years of age is expected to increase by 4-fold.

Amritha.M.Ramakrishnan, a pharmaceutical industry analyst, said: “The coming decade will be a transforming period for the overall prostate cancer therapeutics market. After a stagnant period of growth, the last two years saw the approval of some of the biggest drugs in the prostate cancer therapeutics market. Targeted therapies like Zytiga and Xtandi will be the primary drivers of the market. Studies suggest that there is an overall improvement in survival rates with these newly approved drugs. This has helped in gaining the confidence of physicians and patients around the world. In addition, the pipeline of drugs in development looks very promising. For clinically localised prostate cancer, surgery and radiation will continue to be the dominating therapies. With the prostate cancer market becoming more and more competitive, the market will be driven by more cost effective and clinically significant products”.

The US is currently the leading national market, while emerging countries like China and India are predicted to play a significant role in the second half of the forecast period. This report provides revenue forecasts to 2023 for the global prostate cancer therapeutics market. This report shows revenue forecasts to 2023 at overall world market, submarket and national level. It forecasts world sales for the following submarkets:

Prostate cancer drugs market: including Zytiga, Lupron, Zoladex, Casodex, Taxotere, Provenge, Jevtana and Xtandi

Prostate cancer devices market: including brachytherapy, radical prostatectomy, external beam radiation therapy, cryotherapy and high intensity focused ultrasound

It also discusses the marketed products, products in pipeline, commercial news, strengths, weaknesses, opportunities and threats analysis. The study also includes Porter’s five force analysis to understand the environment in which the companies operate.